“…Due to this variation it is difficult to distinguish PBP mutations involved in resistance development from alterations present due to the distinct origin of the gene. Comparison of a large number of sequences from resistant clinical isolates revealed that at least one of two sites is changed in most resistant PBP2x isolates, both of which are located in the active site cavity of the enzyme: Q552E close to the K547TG triad and T338A(P,G) within the S337TMK motif (3,7,14,43,44,47,54,57). Curiously, most of the many PBP2x mutations identified in spontaneous cefotaxime-resistant laboratory mutants are distinct from changes seen in clinical isolates, including the T338 mutation (32), suggesting that other selective forces are acting outside the laboratory.…”